Crispr Therapeutics AG (CRSP) CEO Sells $894,000.00 in Stock
Crispr Therapeutics AG (NASDAQ:CRSP) CEO Rodger Novak sold 50,000 shares of the firm’s stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $17.88, for a total transaction of $894,000.00. Following the sale, the chief executive officer now owns 1,262,711 shares of the company’s stock, valued at $22,577,272.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Shares of Crispr Therapeutics AG (NASDAQ:CRSP) traded down 1.85% during mid-day trading on Friday, hitting $16.97. 102,831 shares of the stock were exchanged. The stock has a 50-day moving average price of $20.11 and a 200 day moving average price of $19.22. Crispr Therapeutics AG has a 52-week low of $11.63 and a 52-week high of $25.00. The firm’s market cap is $675.58 million.
TRADEMARK VIOLATION NOTICE: “Crispr Therapeutics AG (CRSP) CEO Sells $894,000.00 in Stock” was originally posted by Financial Market News and is owned by of Financial Market News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at http://www.financial-market-news.com/crispr-therapeutics-ag-crsp-ceo-sells-894000-00-in-stock/1406468/.
A number of analysts have weighed in on CRSP shares. Piper Jaffray Companies set a $21.00 price objective on shares of Crispr Therapeutics AG and gave the company a “buy” rating in a research note on Thursday, February 16th. Chardan Capital started coverage on shares of Crispr Therapeutics AG in a research note on Monday, March 27th. They set a “buy” rating and a $23.50 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $23.10.
A number of institutional investors have recently modified their holdings of the company. Clough Capital Partners L P purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth approximately $16,676,000. Franklin Resources Inc. purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth approximately $14,389,000. New Leaf Venture Partners L.L.C. purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth approximately $11,882,000. Orbimed Advisors LLC purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth approximately $7,541,000. Finally, Novo A S purchased a new stake in shares of Crispr Therapeutics AG during the fourth quarter worth approximately $4,524,000. Institutional investors own 0.01% of the company’s stock.
Crispr Therapeutics AG Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.